GHK-Cu (copper-bound tripeptide) — regenerative copper carrier
In short
Copper-binding tripeptide studied in dermatological models for modulating collagen synthesis and tissue regeneration.
Overview
GHK-Cu is a naturally occurring copper tripeptide found in human plasma, saliva, and urine. Plasma levels decline from ~200 ng/ml at age 20 to ~80 ng/ml by age 60. Research shows it affects 31.2% of human genes and promotes wound healing, collagen synthesis, and anti-aging effects. Note: Injectable GHK-Cu is not
Topical GHK-Cu penetrates skin layers to deliver copper directly to target tissues. Activates fibroblasts, stimulates collagen and elastin synthesis, promotes angiogenesis, and modulates inflammatory responses for optimal skin regeneration
Molecular information
First-order decay curve at 0.5h half-life from literature. Educational only.
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
Activation of type I and III collagen synthesis + reduction of TGF-β1-induced scarring. Topical 0.05-0.2% cream gives 30-40% wrinkle reduction in 12 weeks.
Redness at injection site
common
Metallic taste (systemic)
uncommon
Skin pigmentation darkening with prolonged topical use
rare
7 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Pickart — Gene expression
In vitro | 10 nM | 48 h | 4192 genes activated in primary fibroblasts
Biomed Res Int · 2012
View the studyFinkley — Skin clinical trial
Clinical (n=71) | 0.1% cream 2x daily | 12 weeks | -30-40% wrinkles, +70% collagen density
Int J Cosmet Sci · 2005
View the studyInformation about GHK-Cu is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadEducation
No comments yet. Be the first.
Comments are reviewed before publishing.
